To further corroborate our observations, we collected a sample cohort of advanced NSCLC patients with EGFR mutations who received third‐generation TKI treatment, with clinicopathological data (Table S1, Supporting Information). This evidence concerns the gene EGFR and non-small cell lung carcinoma.